Seagen Competitors

Amgen (NASDAQ:AMGN) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

75.2% of Amgen shares are owned by institutional investors. Comparatively, 87.2% of Seagen shares are owned by institutional investors. 0.4% of Amgen shares are owned by company insiders. Comparatively, 31.1% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Amgen and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Amgen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amgen and Seagen, as reported by MarketBeat.com.

Amgen presently has a consensus target price of $259.4091, suggesting a potential upside of 4.20%. Seagen has a consensus target price of $185.3571, suggesting a potential upside of 29.76%. Given Seagen's stronger consensus rating and higher probable upside, analysts plainly believe Seagen is more favorable than Amgen.

Profitability

This table compares Amgen and Seagen's net margins, return on equity and return on assets.

Risk and Volatility

Amgen has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Summary

Seagen beats Amgen on 9 of the 15 factors compared between the two stocks.

Gilead Sciences (NASDAQ:GILD) and Seagen (NASDAQ:SGEN) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

Insider and Institutional Ownership

76.4% of Gilead Sciences shares are owned by institutional investors. Comparatively, 87.2% of Seagen shares are owned by institutional investors. 0.1% of Gilead Sciences shares are owned by company insiders. Comparatively, 31.1% of Seagen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Gilead Sciences and Seagen's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Gilead Sciences and Seagen's top-line revenue, earnings per share (EPS) and valuation.

Gilead Sciences has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Gilead Sciences has a beta of 0.51, suggesting that its share price is 49% less volatile than the S&P 500. Comparatively, Seagen has a beta of 1.11, suggesting that its share price is 11% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations and price targets for Gilead Sciences and Seagen, as reported by MarketBeat.com.

Gilead Sciences presently has a consensus target price of $97.2308, suggesting a potential upside of 49.33%. Seagen has a consensus target price of $185.3571, suggesting a potential upside of 29.76%. Given Gilead Sciences' higher probable upside, research analysts plainly believe Gilead Sciences is more favorable than Seagen.

Summary

Seagen beats Gilead Sciences on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Seagen and Vertex Pharmaceuticals' revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, indicating that its share price is 21% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Vertex Pharmaceuticals, as reported by MarketBeat.com.

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Vertex Pharmaceuticals has a consensus target price of $293.1250, indicating a potential upside of 37.39%. Given Vertex Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Seagen.

Summary

Vertex Pharmaceuticals beats Seagen on 10 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Seagen and Regeneron Pharmaceuticals' revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, indicating that its share price is 70% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Regeneron Pharmaceuticals, as reported by MarketBeat.com.

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Regeneron Pharmaceuticals has a consensus target price of $637.2083, indicating a potential upside of 34.10%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Regeneron Pharmaceuticals is more favorable than Seagen.

Summary

Regeneron Pharmaceuticals beats Seagen on 9 of the 14 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 0.5% of Biogen shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Biogen's net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Seagen and Biogen's revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Biogen, as reported by MarketBeat.com.

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Biogen has a consensus target price of $303.5517, indicating a potential upside of 13.19%. Given Seagen's stronger consensus rating and higher possible upside, analysts clearly believe Seagen is more favorable than Biogen.

Summary

Seagen beats Biogen on 8 of the 15 factors compared between the two stocks.

Seagen (NASDAQ:SGEN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both large-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, valuation, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Insider and Institutional Ownership

87.2% of Seagen shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 31.1% of Seagen shares are held by company insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seagen and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Earnings and Valuation

This table compares Seagen and Alexion Pharmaceuticals' revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Seagen has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, indicating that its share price is 33% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for Seagen and Alexion Pharmaceuticals, as reported by MarketBeat.com.

Seagen presently has a consensus target price of $185.3571, indicating a potential upside of 29.76%. Alexion Pharmaceuticals has a consensus target price of $153.8636, indicating a potential downside of 0.74%. Given Seagen's stronger consensus rating and higher possible upside, analysts clearly believe Seagen is more favorable than Alexion Pharmaceuticals.

Summary

Seagen beats Alexion Pharmaceuticals on 8 of the 14 factors compared between the two stocks.